Recombinant multi-species MIP-3 Beta/CCL19 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MIP-3 Beta/CCL19 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This antimicrobial gene is one of several CC cytokine genes clustered on the p-arm of chromosome 9. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene may play a role in normal lymphocyte recirculation and homing. It also plays an important role in trafficking of T cells in thymus, and in T cell and B cell migration to secondary lymphoid organs. It specifically binds to chemokine receptor CCR7. [provided by RefSeq, Sep 2014]
The Alternative Names of target: MIP-3 Beta, CCL19,C-C motif chemokine 19,Beta-chemokine exodus-3, CK beta-11, Epstein-Barr virus-induced molecule 1 ligand chemokine (EBI1 ligand chemokine, ELC), Macrophage inflammatory protein 3 beta (MIP-3-beta), Small-inducible cytokine A19,ELC,CKb11,MIP3B,MIP-3b,SCYA19

Target products collectionGo to MIP-3 Beta/CCL19 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0744-Ab-1/ GM-Tg-hg-SE0744-Ab-2 Human MIP-3 Beta/CCL19 protein Human
GM-Tg-rg-SE0744-Ab-1/ GM-Tg-rg-SE0744-Ab-2 Rat MIP-3 Beta/CCL19 protein Rat
GM-Tg-mg-SE0744-Ab-1/ GM-Tg-mg-SE0744-Ab-2 Mouse MIP-3 Beta/CCL19 protein Mouse
GM-Tg-cynog-SE0744-Ab-1/ GM-Tg-cynog-SE0744-Ab-2 Cynomolgus/Rhesus macaque MIP-3 Beta/CCL19 monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0744-Ab-1/ GM-Tg-felg-SE0744-Ab-2 Feline MIP-3 Beta/CCL19 protein Feline
GM-Tg-cang-SE0744-Ab-1/ GM-Tg-cang-SE0744-Ab-2 Canine MIP-3 Beta/CCL19 protein Canine
GM-Tg-bovg-SE0744-Ab-1/ GM-Tg-bovg-SE0744-Ab-2 Bovine MIP-3 Beta/CCL19 protein Bovine
GM-Tg-equg-SE0744-Ab-1/ GM-Tg-equg-SE0744-Ab-2 Equine MIP-3 Beta/CCL19 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0744-Ab-1/ GM-Tg-hg-SE0744-Ab-2; GM-Tg-rg-SE0744-Ab-1/ GM-Tg-rg-SE0744-Ab-2;
GM-Tg-mg-SE0744-Ab-1/ GM-Tg-mg-SE0744-Ab-2; GM-Tg-cynog-SE0744-Ab-1/ GM-Tg-cynog-SE0744-Ab-2;
GM-Tg-felg-SE0744-Ab-1/ GM-Tg-felg-SE0744-Ab-2; GM-Tg-cang-SE0744-Ab-1/ GM-Tg-cang-SE0744-Ab-2;
GM-Tg-bovg-SE0744-Ab-1/ GM-Tg-bovg-SE0744-Ab-2; GM-Tg-equg-SE0744-Ab-1/ GM-Tg-equg-SE0744-Ab-2
Products Name MIP-3 Beta/CCL19 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name MIP-3 Beta/CCL19
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MIP-3 Beta/CCL19 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.